stoxline Quote Chart Rank Option Currency Glossary
  
Bristol-Myers Squibb Company (BMY)
42.98  0.31 (0.73%)    07-23 16:00
Open: 42.44
High: 43.075
Volume: 12,579,475
  
Pre. Close: 42.67
Low: 41.9
Market Cap: 87,125(M)
Technical analysis
2024-07-23 4:50:51 PM
Short term     
Mid term     
Targets 6-month :  51.67 1-year :  60.35
Resists First :  44.24 Second :  51.67
Pivot price 41.23
Supports First :  41.21 Second :  39.34
MAs MA(5) :  42.76 MA(20) :  41.37
MA(100) :  45.8 MA(250) :  50.97
MACD MACD :  0.1 Signal :  -0.2
%K %D K(14,3) :  69.8 D(3) :  69.7
RSI RSI(14): 59.2
52-week High :  63.88 Low :  39.34
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ BMY ] has closed below upper band by 12.5%. Bollinger Bands are 0.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 43.13 - 43.29 43.29 - 43.46
Low: 41.46 - 41.66 41.66 - 41.86
Close: 42.66 - 42.96 42.96 - 43.27
Company Description

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Headline News

Tue, 23 Jul 2024
Should You Buy, Sell or Hold Bristol Myers (BMY) Before Q2 Earnings? - Zacks Investment Research

Tue, 23 Jul 2024
Bristol-Myers Squibb (NYSE:BMY) Shares Down 1.5% Following Analyst Downgrade - MarketBeat

Mon, 22 Jul 2024
Bristol Myers Squibb Co. stock rises Monday, still underperforms market - MarketWatch

Mon, 22 Jul 2024
Bristol Myers Squibb's Commitment to Environment, Social and Governance: Our Progress & Aspirational Goals - StockTitan

Sun, 21 Jul 2024
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Orion Portfolio Solutions LLC - American Banking and Market News

Fri, 19 Jul 2024
Bristol-Myers Squibb - Investors Are Too Long-Term Focused (NYSE:BMY) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NYSE
Sector:
Healthcare
Industry:
Drug Manufacturers - General
Shares Out 2,030 (M)
Shares Float 2,020 (M)
Held by Insiders 0.1 (%)
Held by Institutions 79.1 (%)
Shares Short 31,620 (K)
Shares Short P.Month 28,730 (K)
Stock Financials
EPS -3.1
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 8.14
Profit Margin -13.5 %
Operating Margin 19.2 %
Return on Assets (ttm) 5.3 %
Return on Equity (ttm) -25.4 %
Qtrly Rev. Growth 4.6 %
Gross Profit (p.s.) 0
Sales Per Share 22.42
EBITDA (p.s.) 8.95
Qtrly Earnings Growth 0 %
Operating Cash Flow 13,720 (M)
Levered Free Cash Flow 16,370 (M)
Stock Valuations
PE Ratio -13.87
PEG Ratio -17.3
Price to Book value 5.28
Price to Sales 1.91
Price to Cash Flow 6.35
Stock Dividends
Dividend 0.6
Forward Dividend 0
Dividend Yield 1.3%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android